This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

M. Brian Fennerty, MD
Oregon Health Sciences University Portland

JAMA. 1996;276(14):1135.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Dr Soll and colleagues¹ acknowledge that treatment regimens for peptic ulcer disease remain cumbersome and recognize the need for more data from rigorous controlled trials; I am in total agreement. However, they follow this statement by mentioning that 3 regimens (a bismuth-based triple-therapy regimen, a proton pump inhibitor [PPI], and a PPI with 2 of these antibiotics: clarithromycin, metronidazole, or amoxicillin), out of the many described in the literature, are cautiously recommended. To my knowledge, there are no controlled prospective trials of US patients on which to base this recommendation. Furthermore, there are no community-based studies looking at the effectiveness of any single regimen.

It is further stated that the combination of ranitidine bismuth subcitrate and clarithromycin, despite having received approval by the Food and Drug Administration (FDA), should not be used without the addition of tetracycline or amoxicillin. I am unaware of any such data suggesting . . . [Full Text PDF of this Article]

Footnotes
Edited by Margaret A. Winker, MD, Senior Editor, and Phil B. Fontanarosa, MD, Senior Editor.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?